Pharmacodynamics in the Evaluation of Drug Regimens

Kays MB Graff MA . Broth microdilution and E-test for determining fluoroquinolone activity against Streptococcus pneumoniae . Ann Pharmacother 2002; 36: 416–22.

Johnson DM Jones RN Erwin ME . Anti-streptococcal activity of SB-265805 (LB20304), a novel fluoronaphthyridone, compared with five other compounds, including quality control guidelines. Diagn Microbiol Infect Dis 1999; 33: 87–91.

Jones RN Erwin ME Biedenbach DJ Johnson DM Pfaller MA . Development of in vitro susceptibility testing methods for gemifloxacin (formerly LB20304a or SB-265805), an investigational fluoronaphthyridone. Diagn Microbiol Infect Dis 1999; 35: 227–34.

Jones RN Johnson DM Erwin ME Beach ML Biedenbach DJ Pfaller MA , The Quality Control Study Group. Comparative antimicrobial activity of gatifloxacin tested against Streptococcus spp. including quality control guidelines and E-test method validation. Diagn Microbiol Infect Dis 1999; 34: 91–8.

Bolmstrom A Karlsson A . The influence of CO₂ incubation on MICs of quinolones tested with Streptococcus pneumoniae and Haemophilus influenzae (abstract D-35). In: Proceedings of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 28–October 1, 1997.

Andrews JM Bradley JE Wise R . Comparison of E-tests with conventional agar MIC. J Antimicrob Chemother 1993; 31: 802–3.

Holt HA Bowker K Bedord KA Reeves DS MacGowan AP . Comparison of E test with conventional agar MICs for quinolones (letter). J Antimicrob Chemother 1994; 33: 356.

Jones RN Erwin ME Croco JL . Critical appraisal of E-test for the detection of fluoroquinolone resistance. J Antimicrob Chemother 1996; 38: 21–5.

Jones RN . Method preferences and test accuracy of antimicrobial susceptibility testing. Updates from the College of American Pathologists Microbiology Surveys Program. Arch Pathol Lab Med 2001; 125: 1285–9.

Lacy MA Lu W Xu X Tessier PR Nicolau DP Quintiliani R . Pharmacodynamic comparison of levofloxacin, ciprofloxacin and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob Agents Chemother 1999; 43: 672–7.

Craig WA Andes DR . Correlation of the magnitude of the AUC₂₄/MIC for 6 fluoroquinolones against Streptococcus pneumoniae with survival and bacteriocidal activity in an animal model (abstract 289). In: Proceedings of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 17–20, 2000.

Craig WA . Pharmacodynamics of antimicrobials: General concepts and applications. In: Nightingale CH Murakawa T Ambrose PG , eds. Antimicrobial pharmacodynamics in theory and clinical practice. New York: New York, 2001: 1–22.

Ambrose PG Grasela DM Grasela TH Passarell J Mayer HB Pierce PF . Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infection. Antimicrob Agents Chemother 2001; 45: 2793–7.

Forrest A Nix DE Ballow CH Goss TF Birmingham MC Schentag JJ . Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 1073–81.

Forrest A Chodosh S Amantea MA Collins DA Schentag JJ . Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis. J Antimicrob Chemother 1997; 40 (suppl A):45–57.

Preston SL Drusano GL Berman AL Fowler CL Chow AT Dornseif B . Pharmacodynamics of levofloxacin — A new paradigm for early clinical trials. JAMA 1998; 279: 125–9.

Ambrose PG Grasela DM . The use of Monte Carlo simulation to examine the pharmacodynamic variance of drugs: Fluoroquinolone pharmacodynamics against Streptococcus pneumoniae . Diagn Microbiol Infect Dis 2000; 38: 151–7.

Ambrose PG Quintiliani R . Limitations of single point pharmacodynamic analysis (letter). Pediatr Infect Dis J 2000; 19: 769.

Kays MB Denys GA . Fluoroquinolone susceptibility, resistance, and pharmacodynamics versus clinical isolates of Streptococcus pneumoniae from Indiana. Diagn Microbiol Infect Dis 2001; 40: 193–8.

Schentag JJ Gilliland KK Paladino JA . What have we learned from pharmacokinetic and pharmacodynamic theories? Clin Infect Dis 2001;32 (suppl 1):s39–46.

Dudley MN Ambrose PG . Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints: Ready for primetime. Curr Opin Microbiol 2000; 3: 515–21.

Drusano GL Preston SL Hardalo C Banfield C Andes D Vesga O . Use of preclinical data for selection of a Phase II/III dose and identification of a preclinical MIC breakpoint. Antimicrob Agents Chemother 2001; 45: 13–22.

Sinus and Allergy Health Partnership. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Otolaryngol Head Neck Surg 2000; 123 (suppl 1):1–32.

Drusano GL . Human pharmacodynamics of anti-infectives: Determination from clinical trial data. In: Nightingale CH Murakawa T Ambrose PG , eds. Antimicrobial pharmacodynamics in theory and clinical practice. New York: New York, 2001: 303–25.